B-cell Malignancies Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about B-cell Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Chronic Lymphocytic LeukemiaB-cell Malignancies
Curis, Inc.108 enrolled1 locationNCT07271667
Recruiting
Phase 1

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin's Lymphoma+1 more
AbbVie150 enrolled39 locationsNCT05618028
Recruiting
Phase 1Phase 2

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

B-cell Malignancies
AstraZeneca174 enrolled29 locationsNCT06542250
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies

B-cell Malignancies
Sheba Medical Center50 enrolled1 locationNCT07135466
Recruiting
Phase 1

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc60 enrolled9 locationsNCT05780034
Recruiting
Phase 1Phase 2

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

B-cell Malignancies
Shenzhen Geno-Immune Medical Institute200 enrolled2 locationsNCT03050190
Recruiting
Phase 1Phase 2

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

B-cell Malignancies
Shenzhen Geno-Immune Medical Institute100 enrolled4 locationsNCT03125577